Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.

Advertisement

Related Content

Erivedge May Be The Gleevec Of Hedgehog Inhibitors
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial
Erivedge BCC Approval Buoys Hedgehog Fans, But Pathway Needs Proof In Other Cancers
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
Hope At ASH For Failed Pfizer Leukemia Drug Mylotarg
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012
Curis/Genentech Report Positive Phase II Results For Vismodegib
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS004894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel